New indications for antidepressants.
The second and third generation of antidepressants, i.e., the selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine, are proving to be useful in a variety of seemingly diverse disorders, including most anxiety disorders. In addition to receiving approval from the U.S. Food and Drug Administration (FDA) for major depressive disorder, some of the newer antidepressants have received FDA approval for other disorders, e.g., generalized anxiety disorder (venlafaxine), bulimia nervosa (fluoxetine), obsessive-compulsive disorder (fluvoxamine, paroxetine, sertraline, and fluoxetine), social phobia (paroxetine), panic disorder (sertraline, paroxetine), and posttraumatic stress disorder (sertraline). In controlled studies, these agents have also shown usefulness in premenstrual dysphoric disorder, borderline personality disorder, obesity, smoking cessation, and alcoholism. This article describes the new and potential indications for recently developed antidepressants and the studies that suggested these indications.
Schatzberg
A F
AF
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Calif 94305-5548, USA.
D000437:Alcoholism / Q000188:drug therapy / Q000453:epidemiology; D000928:Antidepressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D003866:Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy / Q000453:epidemiology; D001068:Feeding and Eating Disorders / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology; D011293:Premenstrual Syndrome / Q000188:drug therapy / Q000453:epidemiology; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy / Q000453:epidemiology
D000928:Antidepressive Agents